Ro's weak cross-sell and ED reliance
Ro and the telehealth capital cycle
The weak cross sell showed that Ro was not yet a broad consumer health bundle, it was still mostly an ED subscription business with a few adjacent add ons. In practice, that meant a customer often came in for one stigmatized, high intent need, filled a prescription, and left, instead of turning into a multi product patient using hair loss, fertility, or dermatology over time. That kept lifetime value low and left growth dependent on constantly finding new ED buyers.
-
Ro’s original wedge was conditions like ED, hair loss, and herpes, where an online intake, asynchronous clinician review, and home delivery felt easier than a clinic visit. But by 2021, Roman still made about 60% of revenue, showing adjacent categories were not big enough to change the mix.
-
Hair loss looked adjacent on paper, but the buying motion is different. ED is urgent and emotional, while hair loss is easier to comparison shop because the drugs are generic and widely available. That makes switching easy, weakens loyalty, and limits the value of sharing acquisition costs across products.
-
This is why rising CAC hurt so much. If most revenue still comes from the first product, and yearly churn is around 50%, then each new subscriber has to repay marketing spend quickly. Competitors like Hims, Keeps, and others bidding on the same keywords made that payback harder.
The path forward was to add categories with heavier workflows and higher ongoing spend, not just more generic subscriptions. That is exactly where Ro later found traction, first by building more integrated care pathways and then by scaling obesity care, which finally gave the company a product line large enough to rebalance the business away from its ED roots.